News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kaketsuken Becomes First Japanese Pharmaceutical Company to Implement Medidata Solutions, Inc.’s Integrated Solutions for Randomization, Trial Supply Management and Clinical Data Collection, Management and Reporting in Japanese Trials


10/1/2012 10:19:05 AM

NEW YORK--(BUSINESS WIRE)--Vaccine maker KAKETSUKEN, also known as the Chemo-Sero-Therapeutic Research Institute, has become the first Japanese pharmaceutical company to use the combined capabilities of the Medidata Balance™ randomization and trial supply management (RTSM) solution and Medidata Rave® electronic data capture (EDC), clinical data management and reporting system for a Japanese clinical trial. A leading company in the field of biological products, KAKETSUKEN will use the Medidata Solutions (NASDAQ: MDSO) platform to reduce time, costs and risk in a Phase II clinical trial testing a vaccine, and plans to use the solutions for other future trials.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES